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Anticoagulation is highly beneficial for long-term sec-ondary stroke prevention in patients with atrial fibrilla-
tion (AF); nonetheless, there is a paucity of data addressing 
when anticoagulation can be effectively and safely initiated 
after acute stroke. Data from the recently published observa-
tional multicenter RAF study (Early Recurrence and Cerebral 
Bleeding in Patients With Acute Ischemic Stroke and Atrial 
Fibrillation) suggested that the optimal time for initiating 
anticoagulation treatment for secondary stroke prevention is 
between 4 and 14 days after an acute stroke.1 However, the 
specific risk/benefit balance for any given patient and which 
type of strokes is associated with the highest risk and benefit 
by early anticoagulation remains unclear. Risk stratification 
could help to drive clinician decisions on anticoagulant treat-
ment in this clinical setting.
The aim of this prospective multicenter study was to 
develop and validate a score to predict ischemic events and 
major bleedings at 90 days from an acute ischemic stroke in 
patients with AF.
Methods
The risk factors that correlated with outcome events were isolated 
and included in a new risk stratification score from a prospective 
cohort of patients (derivation cohort). The validation of the results 
obtained in the derivation cohort was performed in different patients 
included in prospective series (validation cohort). Patients included 
in the derivation cohort were not eligible for inclusion in the valida-
tion cohort.
Derivation Cohort
The derivation cohort was extracted from the database of the RAF 
study, a prospective observational study performed between January 
2012 and March 2014 that enrolled consecutive patients with acute 
ischemic stroke with either known or newly diagnosed AF. The meth-
ods and results of RAF study have been described in details.1,2
On admission, the severity of acute stroke was assessed using the 
National Institutes of Health Stroke Scale; all investigators were cer-
tified about the use of this scale.
AF was classified as paroxysmal (episodes terminating spontane-
ously within 7 days), persistent (episodes lasting >7 days requiring 
pharmacological or electric stimulation), or permanent (persisting for 
>1 year, either because cardioversion failed or was not attempted).
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Background and Purposes—This study was designed to derive and validate a score to predict early ischemic events and 
major bleedings after an acute ischemic stroke in patients with atrial fibrillation.
Methods—The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in 
prospective series between January 2012 and March 2014. Older age (hazard ratio 1.06 for each additional year; 95% 
confidence interval, 1.00–1.11) and severe atrial enlargement (hazard ratio, 2.05; 95% confidence interval, 1.08–2.87) 
were predictors for ischemic outcome events (stroke, transient ischemic attack, and systemic embolism) at 90 days from 
acute stroke. Small lesions (≤1.5 cm) were inversely correlated with both major bleeding (hazard ratio, 0.39; P=0.03) 
and ischemic outcome events (hazard ratio, 0.55; 95% confidence interval, 0.30–1.00). We assigned to age ≥80 years 2 
points and between 70 and 79 years 1 point; ischemic index lesion >1.5 cm, 1 point; severe atrial enlargement, 1 point 
(ALESSA score). A logistic regression with the receiver-operating characteristic graph procedure (C statistic) showed an 
area under the curve of 0.697 (0.632–0.763; P=0.0001) for ischemic outcome events and 0.585 (0.493–0.678; P=0.10) 
for major bleedings.
Results—The validation cohort consisted of 994 patients included in prospective series between April 2014 and June 2016. 
Logistic regression with the receiver-operating characteristic graph procedure showed an area under the curve of 0.646 
(0.529–0.763; P=0.009) for ischemic outcome events and 0.407 (0.275–0.540; P=0.14) for hemorrhagic outcome events.
Conclusions—In acute stroke patients with atrial fibrillation, high ALESSA scores were associated with a high risk of 
ischemic events but not of major bleedings.   (Stroke. 2017;48:726-732. DOI: 10.1161/STROKEAHA.116.015770.)
Key Words: atrial fibrillation ◼ myocardial infarction ◼ risk stratification ◼ stroke
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A cerebral computed tomography or magnetic resonance was 
performed on admission in all patients to exclude intracranial hem-
orrhage. A second cerebral computed tomographic scan or magnetic 
resonance was performed 48 to 72 hours from stroke onset. The 
sizes of the qualifying infarcts were classified as follows: (1) small, 
when a lesion was ≤1.5 cm, and (2) medium-large, when a lesion 
was >1.5 cm.
Transthoracic echocardiogram was performed within 7 days from 
index stroke. Left atrial enlargement and its severity was defined 
following the American Society of Echocardiography guidelines 
measuring the left atrial diameter or volume, taking into account the 
difference between sexes.3
Differences in the characteristics of patients with or without out-
come events were tested using χ2 test. Specifically, univariate tests 
were applied to compare both clinical characteristics on admission 
and preexisting risk factors for stroke. An exploratory analysis of 
all variables was performed with a divisive hierarchical clustering 
method. Cluster analysis is used to construct smaller groups with 
similar properties from a large set of heterogeneous data. This form 
of analysis is an effective way to discover relationships within a large 
number of variables or observations; the identification of potential 
predictors for outcome events was subsequently made with a series 
of multiple logistic regression models. These variables included risk 
factors, reperfusion therapy, severity of stroke on admission accord-
ing to National Institutes of Health Stroke Scale score, CHA2DS2-
VASc score (2 points for a history of stroke or age ≥75 years, and 1 
point each for age 65 to 74 years, a history of hypertension, diabetes 
mellitus, cardiac failure, vascular disease and sex [female]), and the 
dimension of the ischemic lesions. The day of starting anticoagulant 
treatment was inserted into the models as a continuous or a dichoto-
mized categorical variable either.
Description of the Risk Stratification 
Schema (ALESSA Score)
In the cohort of patients included in the RAF study (derivation cohort), 
older age (hazard ratio 1.06 for 1 added year, standard error 0.0207, 
β-coefficient 0.055, P=0.0025) and severe atrial enlargement (hazard 
ratio 2.05, standard error 0.389, β-coefficient 0.989, P=0.027) were 
shown to be predictive factors for ischemic outcome events occurring 
within 90 days from acute stroke. The characteristics of the patients in 
the derivation cohort with and without outcome events are described 
in Tables I and II in the online-only Data Supplement. Small lesions 
(≤1.5 cm) on computed tomographic scan or magnetic resonance 
imaging were inversely correlated with both hemorrhagic (hazard 
ratio 0.39, standard error 0.491, β-coefficient −1.420, P=0.03) and 
ischemic outcome events (hazard ratio 0.55, standard error 0.314, 
β-coefficient −0.594, P=0.05).1,2 Based on the magnitude of the effect 
(β-coefficient) associated with these variables, we assigned to age 
≥80 years 2 points; age between 70 to 79 years 1 point; the presence 
of an ischemic index lesion >1.5 cm 1 point; and presence of severe 
atrial enlargement 1 point (ALESSA score).
Figure 1. The risk of ischemic outcome events and symptom-
atic intracranial bleedings/major extracranial bleeding according 
to ALESSA score in the derivation cohort. ALESSA indicates 
age ≥80 years (2 points) and between 70 to 79 years (1 point), 
ischemic index lesion >1.5 cm (1 point), severe atrial enlargement 
(1 point).
Table 1. Characteristics of Patients Included in the 
Derivation and Validation Cohorts
 
Derivation Cohort 
(n=854)
Validation Cohort 
(n=994) P Value
Age (mean), y 76.3±9.5 75.8±10.1 NS
NIHSS (mean) 8.9±7.0 8.1±6.4 NS
Sex male 398 (46.6%) 457 (46.0%) NS
Diabetes mellitus 221 (26.0%) 201 (20.2%) 0.004
Hypertension 676 (79.8%) 776 (78.1%) NS
Hyperlipidemia 282 (33.4%) 361 (36.3%) NS
History stroke/TIA 205 (24.3%) 250 (25.2%) NS
Smoking 158 (18.7%) 171 (17.2%) NS
Alcoholism 57 (6.7%) 50 (5.0%) NS
History of CHF 167 (19.6%) 159 (16.0%) 0.045
History of MI 142 (16.8) 92 (9.3%) 0.0001
Paroxysmal AF 316 (37.0%) 456 (43.4%) 0.001
Pacemaker 70 (8.2%) 42 (4.2%) 0.004
r-tPA or 
thrombectomy
201 (23.5%) 329 (33.0%) 0.0001
Moderate/severe 
atrial enlargement
400 (46.9%) 405 (40.7%) 0.008
Small lesion 325 (38.1%) 379 (38.1%) NS
ALESSA score 3–4 295 (34.5%) 408 (41.1%) 0.04
CHA
2
DS
2
-VASc
 2 17 (2.0%) 37 (3.7%)  
 3 55 (6.4%) 97 (9.8%)  
 4 105 (12.3%) 146 (14.7%)  
 5 221 (25.9%) 254 (25.6%)  
 6 240 (28.1%) 318 (32.0%)  
 7 149 (17.4%) 106 (10.7%)  
 8 60 (7.0%) 29 (2.9%)  
 9 7 (0.8%) 7 (0.7%)  
CHA
2
DS
2
-VASc >4 677 (79.3%) 714 (71.8%) 0.0002
Vitamin K 
antagonist
493 62 0.0001
Direct anticoagulant 79 878 0.0001
No anticoagulant 282 53 0.0001
AF indicates atrial fibrillation; ALESSA, age ≥80 years (2 points) and between 
70 to 79 years (1 point), ischemic index lesion >1.5 cm (1 point), severe atrial 
enlargement (1 point); CHA2DS2-VASc, 2 points for a history of stroke or age 
≥75 years, and 1 point each for age 65 to 74 years, a history of hypertension, 
diabetes mellitus, cardiac failure, vascular disease and sex (female); CHF, 
congestive heart failure; MI, myocardial infarction; NIHSS, National Institutes of 
Health Stroke Scale; r-tPA, recombinant tissue-type plasminogen activator; and 
TIA, transient ischemic attack.
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Validation Cohort
The validation cohort consisted of 994 ischemic stroke patients with 
acute stroke and AF seen between April 2014 and June 2016 deriving 
from several international prospective stroke series. Patients included 
in the validation cohort were those with a reported echocardiogram 
within 7 days among 1161 consecutive patients. Inclusion criteria, 
outcome definition, and statistical analysis were as in the derivation 
cohort.
Patients treated with revascularization (systemic recombinant 
tissue-type plasminogen activator or intravascular thrombectomy) 
were assumed as having a final lesion >1.5 cm if they had a National 
Institutes of Health Stroke Scale score ≥10 prior to treatment.4
Definition of Outcome Events
Outcome events for this study were ischemic outcome events (com-
bination of stroke, transient ischemic attack, and systemic embolism) 
and hemorrhagic outcome events (combination of symptomatic intra-
cranial bleeding and major extracranial bleeding) occurring within 
90 days. Stroke was defined as the sudden onset of a new focal neu-
rological deficit of vascular origin in a site consistent with the terri-
tory of a major cerebral artery and categorized as ischemic. Transient 
ischemic attack was defined as a transient episode of neurological 
dysfunction caused by focal brain ischemia without acute infarction 
at neuroimaging. Systemic embolism was defined as an acute vascu-
lar occlusion of an extremity or organ confirmed by imaging, surgery, 
or autopsy. Hemorrhagic transformation found on neuroimaging 24 
to 72 hours after onset was not considered an outcome event, unless 
they were symptomatic. Major extracranial bleeding was defined as a 
reduction in the hemoglobin level of at least 2 g/dL, requiring a blood 
transfusion of at least 2 U, or symptomatic bleeding in a critical area 
or organ.5
Statistical Analysis
Derivation Cohort
A descriptive analysis with proportions was used to describe the 
derivation cohort and the event rates of ischemic outcome events 
and hemorrhagic outcome events. The 95% confidence interval (CI) 
of event rates using the binomial approximation was calculated. A 
logistic regression analysis was performed with ALESSA risk factors 
as independent variables and ischemic events and major intra- and 
extracranial bleeding as dependent variables. The probability that this 
model would predict the correct classification of individual patients 
(with or without ischemic or hemorrhagic outcome events) was saved. 
Thereafter, the probabilities in a receiver-operating characteristic 
curve against ischemic or hemorrhagic outcome events as dependent 
variables were plotted. The areas under the curves for these receiver-
operating characteristic curves represent the ability of the ALESSA 
score to correctly classify risks for ischemic or hemorrhagic outcome 
events, which are also referred to as the C statistic (Harrell’s C).6
Validation Cohort
The same statistical analysis performed in the derivation cohort was 
used in the validation cohort.
Results
Derivation Cohort
In the RAF cohort (Table I in the online-only Data 
Supplement), high scores of the ALESSA score (3 and 4) were 
correlated with ischemic outcome events but not with hemor-
rhagic outcome events (Figure 1). Patient’s characteristics for 
both cohorts are reported in Table 1. Multivariable analysis 
confirmed that ALESSA score, as continuous variable, was an 
independent predictor of ischemic outcome events (odds ratio 
[OR], 1.83 for 1 added point; 95% CI, 1.17–2.87; P=0.008), 
while it was not correlated with hemorrhagic outcome events 
(OR, 1.07 for 1 added point; 95% CI, 0.48–2.40; P=0.8).
Logistic regression with the receiver-operating character-
istic graph procedure to obtain the C statistic showed that the 
area under the curve was 0.697 (0.632–0.763; P=0.0001) for 
ischemic outcome events and 0.585 (0.493–0.678; P=0.10) 
for hemorrhagic outcome events (Figure 2A and 2B). On 
multivariate regression analysis, a score >2 was found to 
be correlated with ischemic outcome events (OR, 2.5; 95% 
CI, 1.4–4.4; P=0.001), while it was found not to correlated 
with hemorrhagic outcome events (OR, 1.1; 95% CI, 0.5–2.4; 
P=0.9).
Validation Cohort
The features of the validation cohort and the relative differ-
ences with the derivation cohort are shown in Table 1. The 
main differences between derivation and validation cohorts 
were that the validation cohort had lower CHA2DS2-VASc 
score compared with the derivation cohort and that 88% of 
the patients in the validation cohort were treated with direct 
anticoagulants compared with 10% in the derivation cohort. 
Figure 2. Logistic regression with the 
receiver operating characteristic graph 
procedure to obtain the C statistic for 
ischemic outcome events within 90 days 
(A) and for major intra- and extracerebral 
bleedings (B) in the derivation cohort.
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A lower risk of composite outcome event was observed in the 
validation cohort (4.9%) compared with the derivation cohort 
(11.5%; Table 2).
In the validation cohort, high scores of the ALESSA score 
were correlated with ischemic outcome events but not with 
hemorrhagic outcome events (Figure 3). Study outcomes are 
reported in Tables 1 and 2.
Multivariable analysis confirmed that ALESSA score as 
continuous variable was an independent predictor of isch-
emic outcome events (OR, 1.69 for 1 added point; 95% CI, 
1.00–2.85; P=0.048), while it was not correlated with hemor-
rhagic outcome events (OR, 1.19 for 1 added point; 95% CI, 
0.68–2.09; P=0.5).
Logistic regression with the receiver-operating character-
istic graph procedure to obtain the C statistic showed that the 
area under the curve was 0.646 (0.529–0.763; P=0.009) for 
ischemic outcome events within 90 days and 0.407 (0.275–
0.540; P=0.14) for hemorrhagic outcome events (Figure 4A 
and 4B).
On multivariate regression analysis, a score >2 was margin-
ally found not to be associated with ischemic outcome events 
(OR, 2.07; 95% CI, 0.93–4.67; P=0.07), while it was found 
not to be correlated with hemorrhagic outcome events (OR, 
0.7; 95% CI, 0.3–1.8; P=0.4).
Discussion
In patients with ischemic stroke with AF, the risk of stroke 
recurrence has been found to be particularly high in the 
first 2 weeks after the acute event.7 Despite this observa-
tion, in these patients, there are no comparative studies on 
the optimal timing of starting of anticoagulation. Thus, such 
a decision hinges on the assessment of the competing risks 
for early thromboembolic recurrences and hemorrhagic 
transformation.
The RAF study suggested that in patients with acute stroke 
and AF, the best time for initiating anticoagulation treatment 
for secondary stroke prevention ranges from 4 to 14 days from 
stroke onset. In patients with acute stroke and AF, clinicians 
would like to be able to identify those patients who may be 
candidates to prompt anticoagulation, with a risk of early 
recurrence high enough to justify the risk of cerebral bleed-
ing associated with early anticoagulant treatment. Several 
risk factors could be used to estimate the risk of recurrence 
or cerebral bleeding.8 In this study, a novel risk factor–based 
approach to stroke risk stratification in patients with acute 
stroke and AF has been validated. Within 90 days from index 
stroke, patients with ALESSA score between 0 and 2 have 
a low risk for both ischemic recurrent events and bleeding. 
During the same period of time, patients with scores 3 or 4 
have a statistically significantly increase in the risk of isch-
emic recurrent events but not of the risk of bleeding. These 
results may be explained by the fact that the ALESSA score 
was built picking up from the derivation cohort the variables 
that correlated with ischemic recurrence and not with hem-
orrhagic transformation. Our clinical interpretation is that 
patients with score 3 or 4 could have the best benefit from an 
early anticoagulation. The optimal time of starting anticoagu-
lant treatment might not be the same with all anticoagulants 
because of the different promptness of action. Indeed, direct 
anticoagulants reach therapeutic level in ≈2 hours, while vita-
min K antagonists may take days to achieve it.
The C statistic showed a 0.646 predictive value of the 
ALESSA score for ischemic events. This value, although not 
outstanding, is of the same order of magnitude of the 0.606 
predictive value of the CHA2DS2-VASc for long-term risk of 
thromboembolism in patients with AF.9 Notably, CHA2DS2-
VASc score is currently considered the best score to choose 
the type of antithrombotic treatment for long-term stroke 
prevention in patients with AF. Indeed, in patients with acute 
stroke and AF, it was found that CHA2DS2-VASc score was a 
predictive factor for ischemic recurrence occurring as early 
as within 90 days from stroke onset.8 However, in this study, 
Table 2. End Points in the Derivation and Validation Cohorts 
by Different Oral Anticoagulants
 
Derivation Cohort 
(n=854)
Validation Cohort 
(n=994)
Recurrent ischemic event (90 days) 66 (7.7%) 27 (2.7%)
 Ischemic stroke 50 22
 TIA 9 4
 Systemic embolism 7 1
Hemorrhagic event (90 days) 31 (3.6%) 22 (2.2%)
  Symptomatic intracranial 
bleeding
29 14
 Major extracranial bleeding 2 8
Recurrent ischemic event (at 90 days)
 Vitamin K antagonist 35/493 (7.1%) 3/62 (4.8%)
 Direct anticoagulant 4/79 (5.1%) 21/878 (2.4%)
Hemorrhagic event (at 90 days)
 Vitamin K antagonist 15/493 (3.0%) 6/62 (9.6%)
 Direct anticoagulant 2/79 (2.5%) 21/878 (1.6%)
TIA indicates transient ischemic attack.
Figure 3. The risk of ischemic outcome events and symptomatic 
intracranial bleedings/major extracranial bleeding according to 
ALESSA score in the validation cohort. ALESSA indicates age ≥80 
years (2 points) and between 70 to 79 years (1 point), ischemic 
index lesion >1.5 cm (1 point), severe atrial enlargement (1 point).
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CHA2DS2-VASc score was a predictive factor, along with isch-
emic recurrent event, of early symptomatic cerebral bleeding. 
Therefore, CHA2DS2-VASc score cannot be used to identify 
those patients with acute stroke and AF who benefit the most 
of early anticoagulation.
This study has some limitations. The validation cohort had 
a lower CHA2DS2-VASc score compared with the derivation 
cohort; furthermore, ≈88% of the patients in the validation 
cohort were treated with direct oral anticoagulants compared 
with ≈10% of the patients in the derivation cohort. These dif-
ferences because of different time periods of data collection, 
probably, lead to a lower rate of outcome events (the com-
bination of ischemic and hemorrhagic events) in the valida-
tion cohort compared with the derivation cohort (4.9% versus 
10.8%, respectively). The low rates of events in the validation 
cohort may have led to reduce statistical power in the study. 
However, the study has the advantage to mirror the changes 
in clinical practice in this clinical setting. In the patients of 
derivation cohort treated mainly with vitamin K antagonists, 
a key determinant of hemorrhagic risk (and also efficacy of 
infarct prevention) would be the international normalized 
ratio. Unfortunately, the international normalized ratio at the 
moment of the outcome event was not available.
Our study has also some strengths as the sample size and the 
prospective design. In view of the absence of any randomized 
trial, the ALESSA score based on simple and easily available 
variables could assist stroke physicians in better managing 
acute cerebral ischemia in patients with AF. Furthermore, the 
score may be used as a selection criteria for trials evaluating 
early anticoagulation in patients with acute stroke and AF.
Conclusions
ALESSA is a novel, simple risk stratification score for 
patients with acute stroke and AF based on age, lesion size, 
and the presence of severe atrial enlargement. High scores of 
this schema are associated with the risk of ischemic recurrent 
events but not with bleeding. Therefore, patients with acute 
stroke and AF and an ALESSA score higher than 2 are candi-
dates to an early anticoagulation treatment.
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